Abstracts tagged "Patient reported outcomes"

Abstract Number: 1674 • ACR Convergence 2024
Variability in Pain and Depression Measures Between Adolescent Patients with Rheumatic Disease and Caregivers
Sarah Baluta¹, Homaira Rahimi², Michelle Swanger-Gagne³, Susan Yussman³ and Christina Schutt³, ¹University of Rochester Medical Center, Syracuse, NY, ²University of Rochester, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: The Patient Reported Outcome Measures Information System (PROMIS) has been validated for pediatric rheumatology conditions in several domains including, physical ability, mental health, and…
Abstract Number: 2161 • ACR Convergence 2024
Parent and Youth Report of Psychosocial Functioning in Chronic Childhood Vasculitis
Camille Wilson¹, Kimberly Morishita², Else Bosman³, Alana Leever⁴, Mahmoud Kallash⁵, Anne Dawson¹, David Cabral⁶ and Vidya Sivaraman⁷, and the PedVas investigator network, ¹Nationwide Children's Hospital, Columbus, OH, ²University of British Columbia - Vancouver, Vancouver, BC, Canada, ³UBC, Vancouver, BC, Canada, ⁴Nationwide Children's Hospital, Ohio State University, Columbus, OH, ⁵Nationwide Children's Hosptial, Columbus, OH, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Nationwide Children's Hospital/ The Ohio State University, Columbus, OH
Background/Purpose: Collaborative research efforts have allowed great strides to advance treatment and care for pediatric patients living with chronic vasculitis. However, little research has been…
Abstract Number: 2396 • ACR Convergence 2024
PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE
Anna Korogodina¹, Erin Sundel¹, Yaroslav Markov², Vasileios Kyttaris³, Julianne O'Connell¹ and Suzanne Krishfield¹, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Yale School of Medicine, New Haven, ³BIDMC, Boston, MA
Background/Purpose: SLE-related outcomes are traditionally assessed by clinician-derived measures. However, these assessments often do not fully capture how patients experience their disease. We assessed the alignment…
Abstract Number: 0356 • ACR Convergence 2024
Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study
Hubert Marotte¹, Laure Gossec², Vered ABITBOL³, Eric SENBEL⁴, Guillaume BONNAUD⁵, Xavier ROBLIN⁶, Yoram BOUHNIK⁷, Stéphane NANCEY⁸, Nicolas MATHIEU⁹, jérôme FILIPPI¹⁰, Lucine VUITTON¹¹, Stéphane NAHON¹², Azeddine Dellal¹², Alice DENIS¹³, Caroline HABAUZIT¹³, Salim BENKHALIFA¹³ and Guillaume BOUGUEN¹⁴, ¹Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ²Sorbonne Université, Paris, France, ³Cochin University Hospital, Paris, France, ⁴Medical practice, Marseille, Marseille, France, ⁵Ambroise Paré Clinic, Toulouse, France, ⁶Saint-Etienne University Hospital, Saint-Etienne, France, ⁷Institut des MICI, Paris IBD Center, Neuilly-Sur-Seine, France, ⁸Hospices Civils de Lyon, Lyon, France, ⁹Clinic of Cèdres, Echirolles, France, ¹⁰Saint-Jean Clinic, Cagnes sur Mer, France, ¹¹Besançon university hospital, Besançon, France, ¹²Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France, ¹³Celltrion Healthcare France, Issy Les Moulineaux, France, ¹⁴Rennes University Hospital, Rennes, France
Background/Purpose: Biosimilars (BioS) are cost-effective alternatives to reference products for patients with chronic inflammatory rheumatic diseases (CIRD) and inflammatory bowel diseases (IBD), but treatment adherence…
Abstract Number: 0592 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Helena Marzo-Ortega¹, Philip Mease², Maxime Dougados³, Maureen Dubreuil⁴, Marina Magrey⁵, Martin Rudwaleit⁶, Maria Antonietta D'Agostino⁷, Christine de la Loge⁸, Ute Massow⁹, Vanessa Taieb¹⁰, Diana Voiniciuc¹¹ and Atul Deodhar¹², ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁷Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Colombes, France, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In the phase 3 studies, BE MOBILE 1 and 2, bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to…
Abstract Number: 0818 • ACR Convergence 2024
Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Lykke Oernbjerg¹, Brigitte Michelsen², Tore K. Kvien³, Simon Horskjær Rasmussen⁴, Jakub Závada⁵, Kristýna Bubová⁶, Bente Glintborg⁷, Anne Gitte Loft⁸, Ana Maria Rodrigues⁹, Maria Jose Santos¹⁰, Adrian Ciurea¹¹, Michael Nissen¹², Laura Kuusalo¹³, Jarno Rutanen¹⁴, Ziga Rotar¹⁵, Katja Perdan-Pikmajer¹⁵, Bjorn Gudbjornsson¹⁶, Olafur Palsson¹⁷, Daniela DiGuiseppe¹⁸, Mikkel Ostergaard¹⁹ and Merete Hetland²⁰, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴Rigshospitalet Glostrup, Glostrup, Denmark, ⁵Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁶Institute of Rheumatology and Charles University, Prague, Czech Republic, ⁷DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ⁸Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁹Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, ¹⁰Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ¹¹University Hospital Zurich, Zürich, Switzerland, ¹²Geneva University Hospital, Geneva, Switzerland, ¹³University of Turku and Turku University Hospital, Turku, Finland, ¹⁴Tampere University Hospital, Tampere, Finland, ¹⁵University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁶Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁷University of Iceland and Skåne University Hospital, Reykjavik, Iceland, ¹⁸Karolinska Institutet, Stockholm, ¹⁹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: While the Axial Spondyloarthritis Disease Activity Score based on C-reactive protein (ASDAS) is recommended for assessment of disease activity in patients with axial spondyloarthritis…
Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Shilpa Venkatachalam¹, Kelly Gavigan², Erik Stone³, Angela Degrassi², Laura Stradford⁴, David Curtis², Esteban Rivera⁵ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
Abstract Number: 1360 • ACR Convergence 2024
Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Urbano Sbarigia¹, Jing Zhao², Jackie Kwong², Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Despite scientific advances and the availability of new treatments for rheumatoid arthritis (RA), many RA patients still cannot achieve the therapeutic goal of low…
Abstract Number: 1675 • ACR Convergence 2024
Extended Validation of the IgG4-Related Disease Symptom Severity Index (SSI)
Isha Jha¹, Grace McMahon¹, Guy Katz¹, Shruthi Srivatsan¹, Caleb Bolden¹, Ana Fernandes¹, Cory Perugino¹, John Stone² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital , Harvard Medical School, Concord, MA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: The Symptom Severity Index (SSI) is a patient-reported outcome measure (PROM) developed for IgG4-related disease (IgG4-RD). The SSI assesses symptoms of IgG4-RD and the…
Abstract Number: 2163 • ACR Convergence 2024
Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App
Marc Blanchard¹, Cinja Koller², Patrick Hermann¹, Johanna Mettler¹, Tiffany Prétat³, Pedro Ming Azevedo³ and Thomas Hügle³, ¹Lausanne University Hospital, Lausanne, Vaud, Switzerland, ²Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, ³Lausanne University Hospital, Lausanne, Switzerland
Background/Purpose: Mobile health apps have demonstrated effectiveness in managing chronic musculoskeletal pain syndromes such as fibromyalgia. We developed an app called POCOS for chronic musculoskeletal…
Abstract Number: 2416 • ACR Convergence 2024
The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort
Romina Nieto¹, Rosana Quintana², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Luis Catoggio⁸, Gisela Subils⁹, Carla Gobbi¹⁰, Bordón Florencia Juliana¹¹, Pablo David Ibáñez Peña¹², Leonel Ariel Berbotto¹³, María C. Bertolaccini¹⁴, Diego O. Riseni¹⁵, María De Los Ángeles Gargiulo¹⁶, Cecilia Pisoni¹⁷, Joaquín Martínez Serventi¹⁸, Emilio Buschiazzo¹⁹, Vitalina De Souza Barbosa²⁰, ODIRLEI MONTICIELO²¹, Carolina Albanez de A. Da C. Andrade²², Francinne Machado Ribeiro²³, Eloisa Bonfa²⁴, Eduardo Borba²⁴, Emília Sato²⁵, Alexis Bondi Peralta²⁶, Silvana Donoso²⁷, Gustavo Aroca Martínez²⁸, Hellen Medina²⁸, Alex Echeverri²⁹, Sebastián Molina-Rios³⁰, Manuela Rubio³¹, Rafael López³², Mario Moreno³³, Olga Lidia Vera Lastra³⁴, Mario Pérez Cristóbal³⁵, Carlos Núñez-Álvarez³⁶, luis M Amezcua Guerra³⁷, Ignacio García-Valladares³⁸, Carlos Abud Mendoza³⁹, Dionicio Galarza-Delgado⁴⁰, Marcos Vázquez⁴¹, Astrid Paats⁴², Jorge N. Cieza Calderón⁴³, Ana Mabel Quiroz Alva⁴⁴, Roberto Muñoz Louis⁴⁵, Carina Pizzarossa⁴⁶, Adriana Carlomagno⁴⁷ RV Gamboa-Cardenas⁴⁸, Graciela Alarcon⁴⁹, Urbano Sbarigia⁵⁰, Federico Zazzetti⁵¹, Ashley Orillion⁵², Guillermo Pons-Estel¹ and Bernardo Pons-Estel¹, ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;, Buenos Aires, Argentina, ⁹Hospital Italiano de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ¹⁰Hospital Córdoba, Ciudad de Córdoba, Argentina, Córdoba, Argentina, ¹¹Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ¹²Hospital HIGA San Martín, La Plata, Argentina, La Plata, Argentina, ¹³Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ¹⁴Hospital Padilla, Tucumán, Argentina, Tucumán, Argentina, ¹⁵Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁶Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁷CEMIC, Buenos Aires, Argentina, ¹⁸Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, CABA, Argentina, ¹⁹Hospital Señor del Milagro, Salta, Argentina, Salta, Argentina, ²⁰Hospital das Clínicas, Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ²¹HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ²²Universidade Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, ²³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁵Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ²⁶Hospital del Salvador, Santiago, Chile, ²⁷Clinical Laboratory Hospital Regional Libertador Bernardo O'Higgins, Rancagua, Chile, Rancagua, Chile, ²⁸Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Colombia, Reumatología, Colombia, ³⁰Facultad de Medicina, Universidad Nacional de Colombia. Hospital Universitario Nacional, Bogotá, Colombia, ³¹Centro de Estudios de Reumatología & Dermatología SAS, Bogotá, Colombia, ³²Servicio de Reumatología. Hospital Luís Vernaza, Guayaquil, Ecuador, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ³⁵Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, ³⁷Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ³⁸Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, ⁴⁰UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁴¹Hospital de Clínicas I, Asunción, Paraguay, Asuncion del Paraguay, Paraguay, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital Nacional Edgardo Rebagliatti Martins, Lima, Perú, Lima, Peru, ⁴⁴Hospital Cayetano Heredia, Lima, Perú, Lima, Peru, ⁴⁵Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, ⁴⁶Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁷Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ⁴⁸Universidad Científica del Sur, Lima, Lima, Peru, ⁴⁹The University of Alabama at Birmingham, Birmingham, AL, ⁵⁰Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵¹Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵²Johnson & Johnson Innovative Medicine, Spring House, PA
Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…
Abstract Number: 0357 • ACR Convergence 2024
Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves
Clifton Bingham¹, Emily Molina², Amy Praestgaard³, Stefano Fiore³ and David Cella⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins, Baltimore, MD, ³Sanofi, Bridgewater, NJ, ⁴Northwestern University, Chicago, IL
Background/Purpose: To evaluate changes over time in fatigue measured by Patient Reported Outcome Measures Information System (PROMIS)-Fatigue scores in rheumatoid arthritis (RA) patients treated with…
Abstract Number: 0593 • ACR Convergence 2024
Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast
Alvin F. Wells¹, Arthur Kavanaugh², William Tillett³, Philip S. Helliwell⁴, Marijn Vis⁵, Yuri Klyachkin⁶, Cynthia Deignan⁷, Lichen Teng⁷, Rebecca Wang⁷ and Alexis Ogdie⁸, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University of California San Diego, La Jolla, CA, ³Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵Erasmus MC, Rotterdam, Netherlands, ⁶Amgen, Lexington, KY, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) score is a composite of 3 patient-reported outcomes (PROs): Health Assessment Questionnaire (HAQ), pain visual…
Abstract Number: 0845 • ACR Convergence 2024
Weight Loss, Disease Activity, and Patient Reported Outcomes in Patients with Musculoskeletal and Autoimmune Diseases Taking Weight Loss Therapies
Thomas Riley¹, Kristin Wipfler², Katherine Wysham³, Michael George⁴, Kaleb Michaud⁵ and Joshua Baker⁴, ¹Hopsital of the University of Pennsylvania, Philadelphia, PA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: With the popularity of medication-assisted weight loss, the current study seeks to characterize the association of weight loss, disease activity, and patient reported outcomes…
Abstract Number: 1250 • ACR Convergence 2024
Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren’s Disease
Suzanne Arends¹, Jiyoon C. Choi², Brandon Becker², Teresa Edwards³, Antoine Sreih⁴, Antonia Christodoulou⁴ and Vibeke Strand⁵, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Bristol Myers Squibb, Princeton, ³RTI International, Research Triangle Park, NC, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration of the endocrine glands. Globally, SjD affects between 0.01% and 0.05%…

« Previous Page
1
…
3
4
5
6
7
…
43
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].